STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study.

This page provides detailed information about this publication. Please click on any text which is underlined to find more information.

Authors

Craig A. Erickson, Jeremy Veenstra-VanderWeele, Raun D. Melmed, James T. McCracken, Linmarie Sikich, Lawrence Scahill, Maryann Cherubini, Peter Zarevics, Karen Walton-Bowen, Randall L. Carpenter, Mark F. Bear, Paul P. Wang, Bryan H. King

Title

STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study.

Journal

Journal of Autism and Developmental Disorders

Year

2014

Volume

44

Issue

4

Page(s)

pp. 958-964.

Abstract Link

Read Abstract (New Window)

Publication Format

Journal Article

Efficacy Study/Review

Yes

Scientific Validity

Peer-Reviewed, Open Trial

Keywords

Adolescent / Secondary School Age, Arbaclofen, Autism, Autistic Disorder, Child/Children, GABA Receptor Agonist, Gamma Aminobutyric Acid, Interaction/Withdrawl, Intervention, Irritability, Lethargy, Medication, Pervasive Developmental Disorder (Not Otherwise Specified), Primary / Elementary School Age, Social Skills

---

If you know of any other publications we should list on this page please email info@informationautism.org

Please note that we are unable to supply publications unless we are listed as the publisher. However, if you are a UK resident you may be able to obtain them from your local public library, your college library or direct from the publisher.

---

Publications | Publications Database | Search Publications